Phase II and Phase III attrition rates 2011–2012

Arrowsmith, John, Miller, Philip·2013·Nature Reviews Drug Discovery
DOI 10.1038/nrd4090

Cited by (697)

Items 501–600 of 697

  1. The role of drug metabolism in drug discovery and development : case ospemifene
    Jouko Uusitalo · 2015
  2. Animal Modelling in Psychiatry
    Bart A. Ellenbroek, Jiun Youn · 2016 · Elsevier eBooks
  3. First-Generation Tumor Xenografts: A Link Between Patient-Derived Xenograft Models and Clinical Disease
    Xin Dong, Peter W. Gout, Lu Yi, Yinhuai Wang, Yong Xu, Kuo Yang · 2017 · Molecular and translational medicine
  4. Analysis of Cell Proliferation by Three-Dimensional Culture
    Xiaoyun Tang, David N. Brindley · 2022 · Methods in molecular biology
  5. Preparation of Magnetized Mesenchymal Stem Cells Using Magnetic Liposomes to Enhance Their Retention in Targeted Tissue —Evaluation of Retention and Anti-inflammatory Efficiency in Skeletal Muscle—
    Yusuke Kono · 2022 · YAKUGAKU ZASSHI
  6. Preregistration in Animal Research
    Céline Heinl, Gilbert Schönfelder, Bettina Bert · 2022 · Springer eBooks
  7. Nanomaterials in Pharmaceuticals
    T. Foyez · 2023 · Materials research foundations
  8. 3D Culture Analysis of Cancer Cell Adherence to Ex Vivo Lung Microexplants
    Nickolas G. Diodati, Zadia Dupee, Felipe T. Lima, Jack E. Famiglietti, Ryan A. Smolchek, Ganlin Qu, Yana Goddard, Duy Nguyen, W. Gregory Sawyer, Edward A. Phelps et al. · 2024 · Tissue Engineering Part C Methods
  9. In Vitro 2D and 3D Cell Models of the Human Blood-Brain Barrier: Demonstrating the Beneficial Influence of Shear Stress on Brain Microvascular Endothelial Cell Phenotype
    Keith D. Rochfort, Philip M. Cummins · 2025 · Neuromethods
  10. Nonclinical Safety Assessment: An Introduction for Statisticians
    Ian S. Peers, Marie C. South · 2016 · Statistics for biology and health
  11. Developability Assessment Workflows to De-Risk Biopharmaceutical Development
    Jesús Zurdo, Andreas Arnell, Olga Obrezanova, Noel Smith, Thomas R. A. Gallagher, Ramón Gómez de la Cuesta, Ben Locwin · 2015 · CRC Press eBooks
  12. La Iglesia de Toledo en la Edad Media: organización institucional y formas de vida religiosa. Estado de la cuestión: archivos y descripción de manuscritos
    Enrique Torija Rodríguez · 2017 · Hispania Sacra
  13. Integrating dose estimation into a decision‐making framework for model‐based drug development
    James Dunyak, Patrick Mitchell, Bengt Hamrén, Gabriel Helmlinger, James Matcham, Donald R. Stanski, Nidal H. Al-Huniti · 2018 · Pharmaceutical Statistics
  14. Drug Discovery
    S. Lakshmana Prabu · 2018 · Advances in medical technologies and clinical practice book series
  15. Fine-tuning Muscarinic Cholinergic Transmission in Alcohol Use Disorder
    Chiara Giuliano, Jeffrey W. Dalley · 2020 · Biological Psychiatry
  16. Minds Open : Sustainability of the European regulatory system for medicinal products
    Hoebert, Vonk Raa, van de Laar Cwe · 2014 · Rivm (National Institute for Public Health and the Environment)
  17. A unique multiattribute method to predict success of emerging drug targets
    Sangeetha De, Linda Meredith · 2015 · Drug Discovery Today
  18. Meta-Research on Oncology Trials: A Toolkit for Researchers with Limited Resources
    Rachel P. Riechelmann, Julien Péron, Boštjan Šeruga · 2018 · The Oncologist
  19. 3 Dimensional Cell Culture Techniques in Cancer Research
    K. Dhanya, Aditya Menon · 2020 · Springer eBooks
  20. Drug Target Identification and Validation
    Srinivas Gullapalli · 2021 · Springer eBooks
  21. Current and Future Strategies for Improving Drug Discovery Efficiency
    Peter Njogu, Kelly Chibale · 2015
  22. Emerging Technologies and their Role in Regulatory Review
    Thomas J. Colatsky · 2016
  23. Is the Microbiome the Fifth Horseman of the Apocalypse in Drug Discovery? Implications for the Gut–Brain Axis
    Joseph A. Conrad, Craig W. Lindsley · 2017 · ACS Chemical Neuroscience
  24. Feasibility and Utility of MRI and Dynamic 18F-FDG-PET in An Orthotopic Organoid-Based Patient-Derived Mouse Model of Endometrial Cancer
    Heidi Espedal, Hege Fredriksen Berg, Tina Fonnes · 2021 · Research Square
  25. Researchers‘ perspectives on preregistration in animal research
    Cristina Priboi, Boris Mayer, Evie Vergauwe, Bernice S. Elger, Hanno Würbel · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  26. Pathway‐Based Similarity Measurement to Quantify Transcriptomics Similarity Between Human Tissues and Preclinical Models
    Paarth Parekh, Jason S. Sherfey, Begum Alaybeyoglu, Murat Cirit · 2024 · Clinical Pharmacology & Therapeutics
  27. The importance of 3D cell culture in drug discovery and development
    Gamze Demirel, Gürsel Koltuk · 2024 · Frontiers in Life Sciences and Related Technologies
  28. A data-driven journey using results from target-based drug discovery for target deconvolution in phenotypic screening
    Gergely Takács, György Tibor Balogh, Róbert Kiss · 2025 · RSC Medicinal Chemistry
  29. Accomplishment of Toxicity Prediction by CADD Tools
    Niranjan Kaushik, Satendra Kumar · 2025 · Springer eBooks
  30. High-Quality In Vivo Chemical Probes for Protein Kinases Disclosed in 2024
    Ricardo A. M. Serafim, Matthias Gehringer · 2025 · ACS Pharmacology & Translational Science
  31. Global Harmonization in Drug Approval: Bridging Regulatory and Clinical Trial Diversity
    Vani Dawar, Anjali Sharma, Vishnu Mittal · 2026 · Current Indian Science
  32. Insights and perspectives into the etiology of TKI-induced cardiotoxicity
    Vivian Xu, Bagdad Ahmed, Brent Boleslav, Don Mager, Alex Sparreboom, Jason A. Sprowl, Kevin M. Huang · 2026 · ASPET Discovery
  33. 3D bioprinting for cancer modeling and drug screening
    Aurélie Cadiou, Eva‐Laure Matera, Nicolas Ellinger, Lars Petter Jordheim, M. Duruisseaux, Christophe André Marquette, Charles Dumontet · 2026 · Biomarker Research
  34. A survey of researchers’ attitudes to preregistration in animal research reveals multiple perceived barriers to adoption
    Cristina Priboi, Boris Mayer, Evie Vergauwe, Bernice S. Elger, Hanno Würbel · 2026 · PLoS Biology
  35. New prospectives and understanding in drug-induced liver injury considering drug metabolism and immune- and inflammation-related factors
    Tsuyoshi Yokoi · 2014 · Folia Pharmacologica Japonica
  36. Plágio e condutas inadequadas em pesquisa: onde chegamos e o que podemos fazer
    Wallace Chamon · 2013 · Arquivos Brasileiros de Oftalmologia
  37. A Structural Comparison Approach for Identifying Small Variations in Binding Sites of Homologous Proteins
    Ivana Uzelac, Thomas Olsson, Leif A. Eriksson · 2015 · Computational Molecular Bioscience
  38. The Pharmaceutical R&D Productivity Crisis
    Cecilia Karlsson · 2015 · Elsevier eBooks
  39. Translational research in drug discovery — current issues and perspectives
    Yuji Fujita, Yuichi Hanada, Hiroyuki Sayama · 2016 · Folia Pharmacologica Japonica
  40. Reproducibility of biomedical research: Quo vadis?
    Rafael Dal‐Ré, António Bernad, Rafael Garesse · 2016 · Medicina Clínica (English Edition)
  41. Using Human Pluripotent Stem Cell-Derived Neural Cultures to Assess Safety of New Drugs and Chemicals
    Cassiano Carromeu · 2018 · InTech eBooks
  42. How the pharmaceutical industry is changing
    R.G. Hill · 2013 · Physiology News
  43. Challenges and opportunities in rare diseases research
    Claudia G. Gonzaga-Jauregui · 2021 · Elsevier eBooks
  44. Clinical pharmacogenetics
    Anuradha Ramamoorthy, Tristan M. Sissung, Michael A. Pacanowski · 2021 · Elsevier eBooks
  45. Organ-on-a-Chip: Novel In Vitro Model for Drug Discovery
    Geeta Aggarwal, Gaurav Kaithwas, Manjari Singh, Ramesh K. Goyal · 2022 · Springer eBooks
  46. Potential Errors and Corrections in Early Phase Drug Development
    Gerald L. Klein, Roger Morgan · 2022 · Clinical Trials and Practice – Open Journal
  47. Target identification for potential drug discovery
    Saurabh Sharma, J Kumaravel, Gurjeet Kaur, Ajay Prakash, Bikash Medhi · 2023 · Elsevier eBooks
  48. In Vitro Models and Molecular Markers for Assessing Nano-Based Systems Inflammatory Potential
    Renata de Lima, Vitória A. N. Antunes, Taís Germano‐Costa, Mariana Guilger Casagrande · 2023 · Interdisciplinary biotechnological advances
  49. Negative findings but positive contributions in cardiovascular research
    Ken Chen, Chunyu Zeng · 2023 · Life Sciences
  50. In Vitro and In Vivo Metabolism Studies
    Biplab Das, Chandra Prakash · 2023 · Springer eBooks
  51. Discovery of a Novel Lidocaine Metabolite by Human Liver Microsome and Identification of Microbial Species Which Produces the Same Metabolite
    Sho Hori, Hikari Taniguchi, Sota Yoshimura, Kanako Takeda, Ryusei Yamashita, Atsushi Kimishima, Kazuo Harada · 2024 · Chemical and Pharmaceutical Bulletin
  52. From Ideation to Innovation: Integrating Pharmaceutical Innovation and Sustainable Development
    Heba Mohamed Mansour, Aiman Saad El-Khatib · 2024 · World sustainability series
  53. The Roles of Endogenous Opioids in Placebo and Nocebo Effects: From Pain to Performance to Prozac
    Patrick L. Kerr, John M. Gregg · 2024 · Advances in neurobiology
  54. Digitalization in Preclinical Research: Advancements and Implications
    Anna Michalska‐Falkowska, Karine Sargsyan · 2024 · Sustainable development goals series
  55. Revolutionising Neurological Therapeutics: Investigating Drug Repurposing Strategies
    Meenakshi Attri, Asha Raghav, Jyoti Sinha · 2024 · CNS & Neurological Disorders - Drug Targets
  56. Advanced Strategy and Future Perspectives in Drug Delivery System
    Appavoo Umamaheswari, Ayarivan Puratchikody, Sakthivel Lakshmana Prabu, R. Thirumurugan · 2025 · Pharmaceutical science.
  57. A pan-cancer, pan-treatment model for predicting drug responses from patient-derived xenografts
    Shruti Gupta, Vikash K Mohani, Ghita Ghislat, Pedro J. Ballester, Shandar Ahmad · 2025 · NAR Genomics and Bioinformatics
  58. Can Innovation Still Be the Main Growth Driver of the Pharmaceutical Industry?
    Alexander Schuhmacher · 2014 · Perspectives on sustainable growth
  59. Comment offrir à tous un accès aux thérapeutiques innovantes ?
    Jacques L. Cadranel, Perrine Créquit, Thibault Vieira, Anne-Marie Ruppert, Valérie Gounant, A. Lavolé, Marie Wislez · 2015 · Revue des Maladies Respiratoires Actualités
  60. The art and science of the drug discovery pipeline
    William Loging · 2016 · Cambridge University Press eBooks
  61. Preclinical Cancer Models with the Potential to Predict Clinical Response
    Martin Scherzer, Nina Kramer, Christine Unger, Angelika Walzl, Stefanie Walter, Mira Stadler, Markus Hengstschläger, Helmut Dolznig · 2016 · Elsevier eBooks
  62. Using Systems Pharmacology to Advance Oncology Drug Development
    Daniel C. Kirouac · 2016 · AAPS advances in the pharmaceutical sciences series
  63. Non-clinical efficacy-related studies for human medicines: An overview and retrospective analysis of data for a group of approved medicines
    A.C. de Mirandae Figueiredo · 2017 · Regulatory Toxicology and Pharmacology
  64. Nanotoxicity in Cancer Research: Technical Protocols and Considerations for the Use of 3D Tumour Spheroids
    Dania Movia, Adriele Prina‐Mello · 2018 · InTech eBooks
  65. Computational Drug Target Tractability Analysis
    Andrew R. Leach, Chris J. Radoux · 2019 · Elsevier eBooks
  66. Fluorescent Imaging for In Situ Measurement of Drug Target Engagement and Cell Signaling Pathways.
    Nathan P. McMahon, Allison Solanki, Jocelyn Jones, Sunjong Kwon, Young-Hwan Chang, Koei Chin, Michel A. Nederlof, Joe W. Gray, Summer L. Gibbs · 2020 · PubMed
  67. Future Prospects and Challenges in Targeting Cellular and Molecular Mechanisms in Respiratory Diseases
    Nitin Verma, Komal Thapa, Kamal Dua · 2021 · Springer eBooks
  68. A Unidirectional 96-Well Fluidic Culture Platform for Upstream Cell Dosing with Subsequent Downstream Nonlinear and Ascending Exposure Gradients for Real-Time and Cell-Based Toxicity Screening Environments
    Bincy Anu John, David J. Sloan, Timothy C. Jensen · 2021 · Applied In Vitro Toxicology
  69. Transparency in Non-Technical Project Summaries to Promote the Three Rs in Respiratory Disease Research
    Martina Bonassera, Esther Clews, Kelly BéruBé · 2022 · Alternatives to Laboratory Animals
  70. When I use a word . . . Commercial clinical trials
    Jeffrey K Aronson · 2023 · BMJ
  71. Emerging Data Strengthens the Argument That the Microbiome Is the Fifth Horseman of the Drug Discovery Apocalypse
    Craig W. Lindsley · 2017 · ACS Chemical Neuroscience
  72. A statistical framework for assessing pharmacological response and biomarkers using uncertainty estimates
    Dennis Y.Q. Wang, James Hensman, Ginte Kutkaite, Tzen S. Toh, GDSC Screening Team, Jonathan R Dry, Julio Sáez-Rodríguez, Mathew J. Garnett, Michael P. Menden, Frank Dondelinger · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  73. Label‐Free Techniques for Target Discovery and Validation
    Daniel Martinez Molina, Michael A. Dabrowski · 2019 · Methods and principles in medicinal chemistry
  74. Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient
    Alan Talevi, Carolina L. Bellera · 2021 · Springer eBooks
  75. Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient
    Alan Talevi, Carolina L. Bellera · 2022 · Springer eBooks
  76. A Machine Learning and Bioinformatic Analysis Reveals an Associated between Cell Surface Receptor Transcript Levels with Drug Response of Breast Cancer Cells and the Drug Off-Target Effects
    Musalula Sinkala, Krupa Naran, Dharanidharan Ramamurthy, Neelakshi Mungra, Darren Patrick Martin, Stefan Barth · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  77. Data-driven patient stratification and drug target discovery by using medical information and serum proteome data of idiopathic pulmonary fibrosis patients
    Yayoi Natsume‐Kitatani, Mari Nogami Itoh, Yoshito Takeda et al. · 2023 · Research Square
  78. Testing of putative antiseizure drugs in a preclinical Dravet syndrome zebrafish model
    Paige Whyte‐Fagundes, A Vance, A Carroll, F Figueroa, Catherine Manukyan, Scott C. Baraban · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  79. Managing University-Industry Collaborative Innovation in the Pharmaceutical Industry
    Zhongxuan Ma · 2024
  80. Prédiction des constantes cinétiques de complexes protéine-ligand
    Sonia Ziada · 2019
  81. Getting Our ACT Together
    Katrina Gore, Phil Stanley · 2015 · Significance
  82. La sépiaptérine réductase
    Alban Latrémolière · 2016 · médecine/sciences
  83. High-throughput analysis of kinase inhibitor drugs on cardiac function using engineered heart tissue constructs
    Genevieve Conant, Zhao Yimu, Milica Radisic · 2016 · Frontiers in Bioengineering and Biotechnology
  84. Pers P ective sP ecial Focus: Horizons in Medicinal cH e M istry
    Asfar Sohail Azmi · 2014
  85. Bioinspired matrices for in vitro hepatic differentiation
    Liisa K. Kanninen · 2016 · Työväentutkimus Vuosikirja
  86. Causal Inference in Medicine via Mendelian Randomization
    Timothy M. Frayling, Benjamin F. Voight · 2016 · Springer eBooks
  87. Regulatory perspective on the use of lung imaging in drug development
    Laura Fregonese · 2015 · European Respiratory Society eBooks
  88. ADME Properties Leading to Toxicity
    Katya Tsaioun · 2016
  89. Contemporary Considerations for Discovering a Successful Medicine
    Michael M. Hann, Martin K. Bayliss, Andrew R. Leach · 2016 · Elsevier eBooks
  90. How to improve success rates of the compounds acting on CNS using biomarkers.
    S. Katsumata · 2017 · Nihon yakurigaku zasshi. Folia pharmacologica Japonica
  91. Flipping the odds of drug development success through human genomics
    Aroon Dinesh Hingorani, Valerie Kuan, Chris Finan, Felix Alexander Krüger, Anna Gaulton, Sandesh Chopade, Reecha Sofat, Raymond J. MacAllister, John P. Overington, Harry Hemingway et al. · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
  92. Microfluidic Device for Co-culturing Lung Airway Cells on a Suspended Hydrogel: Towards a Biomimetic Lung Airway Model
    Mouhita Humayun · 2016 · TSpace (University of Toronto)
  93. Development of in vitro Drug Screening Platforms Using Human Induced Pluripotent Stem Cell-Derived Cardiovascular Cells
    Yosuke K. Kurokawa · 2017 · Open Scholarship Institutional Repository (Washington University in St. Louis)
  94. Recent Progress and Prospect of Drug Metabolism/Pharmacokinetics Research Contributing to Drug Development
    Tsuyoshi Yokoi, Shingo Oda · 2017 · KAGAKU TO SEIBUTSU
  95. Toxicology Meets Pharmacodynamics and Pharmacokinetics – New Concepts, Models and In Vitro Approaches and Tools
    Tuula Heinonen, Olavi Pelkonen, Hanna Tähti · 2018 · Basic & Clinical Pharmacology & Toxicology
  96. Addressing Genotoxicity Risk in Lead Optimization: A PDE10A Inhibitor Case Study
    Bie M. P. Verbist, Marjolein Crabbe, Freddy Van Goethem · 2018 · Methods and principles in medicinal chemistry
  97. The Integrated Optimization of Safety and DMPK Properties Enabling Preclinical Development: A Case History with S1P 1 Agonists
    Simon Taylor · 2018 · Methods and principles in medicinal chemistry
  98. Future Needs in Issue Resolution of Problems That Arise in Drug Development
    Michael K. Pugsley, Matthew M. Abernathy, Tiffany Montevideo Whitney, Simon Authier, John J. Renger, Michael J. Curtis · 2018 · Elsevier eBooks
  99. Step II: Target Validation
    Pierfausto Seneci · 2018 · Elsevier eBooks
  100. Introduction to Issue Resolution
    Mary Jeanne Kallman · 2018 · Elsevier eBooks